Cagrilintide (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Cagrilintide (research code AM833) is a long-acting acylated analogue of the pancreatic hormone amylin, studied as a once-weekly subcutaneous agent for metabolic weight regulation. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers 0.1 mg (100 mcg) of material, which keeps the arithmetic clean across each titration step.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation used in the Phase 2 dose-finding program, where weekly amounts were roughly doubled every two weeks to manage gastrointestinal tolerability before settling at a maintenance level.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Direct-to-Maintenance) Schedule

The advanced schedule compresses the ramp toward the 4.5 mg maintenance level reached in the Phase 2 trial — the dose that produced the largest average weight reduction. It escalates faster and is less forgiving on gastrointestinal tolerability.

Supplies Needed

• Cagrilintide vials (30 mg): ~1 vial for an 8-week run to maintenance; ~1–2 vials for a 12-week run; ~2 vials for a 16-week run at 4.5 mg weekly.
• Insulin syringes (U-100, 1 mL): one fresh syringe per draw — roughly 8 for 8 weeks, 12 for 12 weeks, 16 for 16 weeks.
• Bacteriostatic water (10 mL): one bottle covers ~3 vials at 3 mL each, so a single bottle is ample for most schedules.
• Alcohol swabs: a single 100-count box comfortably covers an 8–16 week schedule.

Protocol Overview

• Research goal: model appetite and satiety regulation via central amylin-receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 0.6 mg starting, titrated to a 4.5 mg weekly maintenance ceiling.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 0.6 mg step and hold each level for about two weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Target the 4.5 mg maintenance band for the bulk of the published efficacy signal.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Split larger volumes if they exceed a single syringe’s capacity.
• Document each draw — date, volume, remaining material — for reproducibility.

How Cagrilintide Works

Cagrilintide is a synthetic, lipidated analogue of amylin — a hormone co-secreted with insulin from pancreatic beta cells. It engages central amylin receptors to promote satiety, slow gastric emptying and reduce overall food intake. The attached fatty-acid chain markedly extends its plasma half-life to roughly 160–195 hours, which is what makes once-weekly dosing feasible in trials. Because it works through the amylin pathway rather than the incretin axis, it is frequently studied alongside GLP-1 agonists, including the combination with semaglutide investigated as CagriSema.

Reported Benefits & Side Effects

Benefits observed in trials

• About 10.8% average body-weight reduction at the 4.5 mg weekly dose over 26 weeks in the Phase 2 study, versus roughly 3.0% on placebo.
• Dose-dependent efficacy, with the 2.4–4.5 mg range showing the largest reductions.
• In combination with semaglutide 2.4 mg (CagriSema), Phase 3 REDEFINE trials reported approximately 20% weight loss at 68 weeks.
• Complementary mechanism to incretin agonists, supporting combination-therapy research.

Side effects reported

• Predominantly gastrointestinal — nausea, vomiting, diarrhoea and constipation — generally mild-to-moderate and transient.
• Occasional mild redness or irritation at subcutaneous injection sites.
• Effects are most pronounced during escalation and are mitigated by slower titration.

Supporting Lifestyle Factors (Research Context)

• Balanced, protein-forward nutrition consistent with the published study designs.
• Combined resistance and aerobic activity to preserve lean mass.
• Seven to nine hours of sleep, stress management, and attention to hydration and electrolytes as standard trial controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Split volume across sites when it exceeds a comfortable single injection.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols